cs99 - It's all about economics. We own shares of a little biotech that is living hand to mouth with great potential. DM put out a call for partners to do or fund research using ABL on the effects of COVID. He got 3 responses and the effort went forward because of someone else's dime. The company has put out a couple of news releases about ABL and HIV while they were getting close to the end of BoM and not having enough money to do that. IMO the company has done the correct thing and focused on what would bring them and the shareholders the best financial result. 

I don't know if there is an HIV institute like the cancer institute that is fundinding 3 of the 5 trials that Zenith is currently in but something like that would push that research forward. When I took a cursory look at the HIV market and the competing products, it became quite obvious that it was best for the company to continue to focus on ABL's current path with the limited funds that they had to work with. It's unfortunate but our financial reality is what is driving that decision.

tada